|
|
Home
>
About us
>
Company Profile
Company profile
Julphar is a public shareholding company based
in the Emirate of Ras Al Khaimah, UAE. It was
established in the year 1980 under the able
guidance of H H Sheikh Saqr Bin Mohammed Al
Qasimi, the Ruler of Ras Al Khaimah. It is not
only the first pharmaceutical manufacturing
company set-up in Arab Gulf States, but also
continues to be a leading pharmaceutical
producer in the region.
Julphar today has nine world-class,
state-of-the-art production facilities located
in UAE. Its products are marketed on five
continents across the world. The company’s
products come in various dosage forms and target
a number of major therapeutic segments,
including:
|
> Anti -Infectives |
> Central Nervous System |
|
> Endocrinology
|
> Musculoskeletal & Joint Diseases |
|
> Respiratory System
|
> Oral Cavity & Gastrointestinal Tract |
|
> Immunosuppressant
|
> Nutrition and Blood
|
|
> Local Anesthetics
|
> Skin |
|
> Para-Medical
Products |
|
Julphar’s production facilities adhere to the
highest standards of manufacturing practices.
Our commitment to quality and a continuous
endeavor to surpass our own high standards has
led us to procure the ISO 9001 and ISO 14001
certifications.The accreditation of our
injection plant by FDA, and the EU-GMP and GLP
certifications for all our facilities are a
further testimony to our commitment to high
quality. These practices and approvals ensure
that an effective and well-documented framework
is always in place and is strictly followed not
only for manufacturing of high quality products,
but also for the effective use of resources and
reduction of wastes.
In addition to the above, several other support
units such as printing & packaging unit, plastic
dosing cap and aluminum pilfer-proof cap
manufacturing plant, transportation fleet (MENA
COOL), carpentry workshop, construction
division, design division, etc., form part of
the Team Julphar. |
|

“Julphar today boasts of nine state-of-the-art production facilities that produce drugs in various dosage forms targeted at a number of therapeutic segments and exported to a number of countries.” |